A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Nintedanib (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 3 Oct 2018 to 3 Nov 2018.
- 22 Sep 2018 New trial record